{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:01:12Z","timestamp":1791302472217,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T00:00:00Z","timestamp":1153180800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1038\/sj.bjc.6603265","type":"journal-article","created":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T11:03:30Z","timestamp":1153220610000},"page":"253-259","source":"Crossref","is-referenced-by-count":54,"title":["A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia"],"prefix":"10.1038","volume":"95","author":[{"given":"V","family":"L\u00e9vy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Vekhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Chaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sentenac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Raffoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Chast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J P","family":"Marie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,7,18]]},"reference":[{"key":"BF6603265_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0277-5379(89)90018-7","volume":"25","author":"BC Baguley","year":"1989","unstructured":"Baguley BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA, Smith GP (1989) Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. Eur J Cancer Clin Oncol 25: 263\u2013269","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF6603265_CR2","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/(SICI)1097-0142(19971201)80:11+<2205::AID-CNCR7>3.0.CO;2-G","volume":"80","author":"JM Bennett","year":"1997","unstructured":"Bennett JM, Young ML, Andersen JW, Cassileth PA, Tallman MS, Paietta E, Wiernik PH, Rowe JM (1997) Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer 80: 2205\u20132209","journal-title":"Cancer"},{"key":"BF6603265_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/beha.2000.0120","volume":"14","author":"T Buchner","year":"2001","unstructured":"Buchner T, Hiddemann W, Schoch C, Haferlach T, Sauerland MC, Heinecke A (2001) Acute myeloid leukaemia (AML): treatment of the older patient. Best Pract Res Clin Haematol 14: 139\u2013151","journal-title":"Best Pract Res Clin Haematol"},{"key":"BF6603265_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/sj.leu.2402067","volume":"15","author":"Z Cai","year":"2001","unstructured":"Cai Z, Lin M, Wuchter C, Ruppert V, Dorken B, Ludwig WD, Karawajew L (2001) Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation. Leukemia 15: 567\u2013574","journal-title":"Leukemia"},{"key":"BF6603265_CR5","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","volume":"8","author":"BD Cheson","year":"1990","unstructured":"Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8: 813\u2013819","journal-title":"J Clin Oncol"},{"key":"BF6603265_CR6","first-page":"693","volume":"67","author":"CJ Coonley","year":"1983","unstructured":"Coonley CJ, Warrell Jr RP, Young CW (1983) Phase I trial of homoharringtonine administered as a 5-day continuous infusion. Cancer Treat Rep 67: 693\u2013696","journal-title":"Cancer Treat Rep"},{"key":"BF6603265_CR7","first-page":"1189","volume":"6","author":"E Feldman","year":"1992","unstructured":"Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P (1992a) Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 6: 1189\u20131191","journal-title":"Leukemia"},{"key":"BF6603265_CR8","first-page":"1185","volume":"6","author":"E Feldman","year":"1992","unstructured":"Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P (1992b) Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 6: 1185\u20131188","journal-title":"Leukemia"},{"key":"BF6603265_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1432-1033.1977.tb11256.x","volume":"72","author":"M Fresno","year":"1977","unstructured":"Fresno M, Jimenez A, Vazquez D (1977) Inhibition of translation in eukaryotic systems by homoharringtonine. Eur J Biochem 72: 323\u2013330","journal-title":"Eur J Biochem"},{"key":"BF6603265_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1191\/1740774506cn134oa","volume":"3","author":"E Garrett-Mayer","year":"2006","unstructured":"Garrett-Mayer E (2006) The continual reassessment method for dose-finding studies: a tutorial. Clin Trials 3: 57\u201371","journal-title":"Clin Trials"},{"key":"BF6603265_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/jnci\/80.14.1095","volume":"80","author":"JL Grem","year":"1988","unstructured":"Grem JL, Cheson BD, King SA, Leyland-Jones B, Suffness M (1988) Cephalotaxine esters: antileukemic advance or therapeutic failure? J Natl Cancer Inst 80: 1095\u20131103","journal-title":"J Natl Cancer Inst"},{"key":"BF6603265_CR12","first-page":"841","volume":"71","author":"CC Huang","year":"1983","unstructured":"Huang CC, Han CS, Yue XF, Shen CM, Wang SW, Wu FG, Xu B (1983) Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China. J Natl Cancer Inst 71: 841\u2013847","journal-title":"J Natl Cancer Inst"},{"key":"BF6603265_CR13","first-page":"511","volume":"11","author":"MT Huang","year":"1975","unstructured":"Huang MT (1975) Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 11: 511\u2013519","journal-title":"Mol Pharmacol"},{"key":"BF6603265_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/1097-0142(19890301)63:5<813::AID-CNCR2820630502>3.0.CO;2-V","volume":"63","author":"HM Kantarjian","year":"1989","unstructured":"Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ (1989) Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63: 813\u2013817","journal-title":"Cancer"},{"key":"BF6603265_CR15","first-page":"2723","volume":"3","author":"HM Kantarjian","year":"1997","unstructured":"Kantarjian HM, Talpaz M, O'Brien S, Kurzrock R, Gutterman J, Keating MJ, McCredie KB, Freireich EJ (1997) Chronic myelogenous leukemia \u2013 progress at the MD Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. Clin Cancer Res 3: 2723\u20132733","journal-title":"Clin Cancer Res"},{"key":"BF6603265_CR16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U","volume":"92","author":"HM Kantarjian","year":"2001","unstructured":"Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM (2001) Homoharringtonine: history, current research, and future direction. Cancer 92: 1591\u20131605","journal-title":"Cancer"},{"key":"BF6603265_CR17","first-page":"69","volume":"37","author":"K Kuliczkowski","year":"1989","unstructured":"Kuliczkowski K (1989) Influence of harringtonine on human leukemia cell differentiation. Arch Immunol Ther Exp (Warsz) 37: 69\u201376","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"BF6603265_CR18","first-page":"1085","volume":"68","author":"SS Legha","year":"1984","unstructured":"Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP (1984) Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 68: 1085\u20131091","journal-title":"Cancer Treat Rep"},{"key":"BF6603265_CR19","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/cncr.20975","volume":"103","author":"D Marin","year":"2005","unstructured":"Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF (2005) Phase I\/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 103: 1850\u20131855","journal-title":"Cancer"},{"key":"BF6603265_CR20","first-page":"801","volume":"67","author":"JA Neidhart","year":"1983","unstructured":"Neidhart JA, Young DC, Derocher D, Metz EN (1983) Phase I trial of homoharringtonine. Cancer Treat Rep 67: 801\u2013804","journal-title":"Cancer Treat Rep"},{"key":"BF6603265_CR21","first-page":"967","volume":"46","author":"JA Neidhart","year":"1986","unstructured":"Neidhart JA, Young DC, Kraut E, Howinstein B, Metz EN (1986) Phase I trial of homoharringtonine administered by prolonged continuous infusion. Cancer Res 46: 967\u2013969","journal-title":"Cancer Res"},{"key":"BF6603265_CR22","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cncr.11620","volume":"98","author":"S O'Brien","year":"2003","unstructured":"O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM (2003) Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98: 888\u2013893","journal-title":"Cancer"},{"key":"BF6603265_CR23","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","volume":"82","author":"S O'Brien","year":"1993","unstructured":"O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82: 1695\u20131700","journal-title":"Blood"},{"key":"BF6603265_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2307\/2531628","volume":"46","author":"J O'Quigley","year":"1990","unstructured":"O'Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46: 33\u201348","journal-title":"Biometrics"},{"key":"BF6603265_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/sj.bjc.6602969","volume":"94","author":"J O'Quigley","year":"2006","unstructured":"O'Quigley J, Zohar S (2006) Experimental designs for phase I and phase I\/II dose-finding studies. Br J Cancer 94: 609\u2013613","journal-title":"Br J Cancer"},{"key":"BF6603265_CR26","first-page":"1403","volume":"70","author":"N Savaraj","year":"1986","unstructured":"Savaraj N, Lu K, Dimery I, Feun LG, Burgess M, Keating M, Loo TL (1986) Clinical pharmacology of homoharringtonine. Cancer Treat Rep 70: 1403\u20131407","journal-title":"Cancer Treat Rep"},{"key":"BF6603265_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/BF00179432","volume":"3","author":"JA Stewart","year":"1985","unstructured":"Stewart JA, Krakoff IH (1985) Homoharringtonine: a phase I evaluation. Invest New Drugs 3: 279\u2013286","journal-title":"Invest New Drugs"},{"key":"BF6603265_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/BF00258117","volume":"14","author":"Y Takemura","year":"1985","unstructured":"Takemura Y, Ohnuma T, Chou TC, Okano T, Holland JF (1985) Biologic and pharmacologic effects of harringtonine on human leukemia\u2013lymphoma cells. Cancer Chemother Pharmacol 14: 206\u2013210","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6603265_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/0014-5793(89)81546-7","volume":"257","author":"RM Tujebajeva","year":"1989","unstructured":"Tujebajeva RM, Graifer DM, Karpova GG, Ajtkhozhina NA (1989) Alkaloid homoharringtoninie inhibits polypeptide chain elongation in human ribosomes on the step of peptide bond formation. FEBS Lett 257: 254\u2013256","journal-title":"FEBS Lett"},{"key":"BF6603265_CR30","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.leu.2400608","volume":"11","author":"G Visani","year":"1997","unstructured":"Visani G, Russo D, Ottaviani E, Tosi P, Damiani D, Michelutti A, Manfroi S, Baccarani M, Tura S (1997) Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on \u2018in vitro\u2019 growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia 11: 624\u2013628","journal-title":"Leukemia"},{"key":"BF6603265_CR31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1200\/JCO.1985.3.5.617","volume":"3","author":"RP Warrell Jr","year":"1985","unstructured":"Warrell Jr RP, Coonley CJ, Gee TS (1985) Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol 3: 617\u2013621","journal-title":"J Clin Oncol"},{"key":"BF6603265_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF00267945","volume":"23","author":"LJ Wilkoff","year":"1989","unstructured":"Wilkoff LJ, Dulmadge DA, Laster Jr WR, Griswold Jr DP (1989) Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine. Cancer Chemother Pharmacol 23: 145\u2013150","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6603265_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1631\/jzus.2004.0230","volume":"5","author":"XJ Ye","year":"2004","unstructured":"Ye XJ, Lin MF (2004) Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells. J Zhejiang Univ Sci 5: 230\u2013234","journal-title":"J Zhejiang Univ Sci"},{"key":"BF6603265_CR34","first-page":"987","volume":"82","author":"DC Zhou","year":"1995","unstructured":"Zhou DC, Zittoun R, Marie JP (1995) Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer 82: 987\u2013995","journal-title":"Bull Cancer"},{"key":"BF6603265_CR35","first-page":"2031","volume":"50","author":"JY Zhou","year":"1990","unstructured":"Zhou JY, Chen DL, Shen ZS, Koeffler HP (1990) Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 50: 2031\u20132035","journal-title":"Cancer Res"},{"key":"BF6603265_CR36","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1002\/sim.920","volume":"20","author":"S Zohar","year":"2001","unstructured":"Zohar S, Chevret S (2001) The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Stat Med 20: 2827\u20132843","journal-title":"Stat Med"},{"key":"BF6603265_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0169-2607(02)00120-7","volume":"72","author":"S Zohar","year":"2003","unstructured":"Zohar S, Latouche A, Taconnet M, Chevret S (2003) Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. Comput Methods Programs Biomed 72: 117\u2013125","journal-title":"Comput Methods Programs Biomed"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6603265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603265","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:22:22Z","timestamp":1684412542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6603265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,18]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["BF6603265"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6603265","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,18]]}}}